Zheng Li

Title: The Innovative Contributions of Inventor Zheng Li

Introduction

Zheng Li, based in Houston, TX, is an accomplished inventor known for his contributions to the fields of therapeutic and diagnostic imaging. With a total of two patents, Zheng's work focuses on compounds that target vascular endothelial growth factor receptors (VEGFR) and multivalent integrin antagonists, showcasing his commitment to advancing medical science.

Latest Patents

Zheng Li's latest patents include significant innovations in the realm of biotechnology and pharmacology. His first patent, titled "Multivalent ligands targeting VEGFR," discloses compounds that specifically target vascular endothelial growth factor receptors for therapy and imaging purposes. This patent also elaborates on methods for making the compounds and detecting or imaging cells that express VEGFR, emphasizing the utility of quinazoline compounds in medical applications.

The second patent, "Labeled, non-peptidic, multivalent integrin antagonist compounds," addresses multivalent integrin-receptor antagonists, which are beneficial in various therapeutic, prophylactic, and diagnostic imaging modalities. These compounds are instrumental in the imaging, detection, localization, and quantification of biological samples, especially in identifying cancer cells. The patent outlines formulations comprising these compounds that have shown promise in preventing and treating diseases, particularly proliferative conditions such as cancer.

Career Highlights

Throughout his career, Zheng Li has made significant strides in medical research and innovation. He has been associated with The Methodist Hospital Research Institute and The Methodist Hospital System, where he has contributed his expertise to cutting-edge research projects. His work not only showcases his inventive capabilities but also his dedication to improving patient outcomes through innovative medical solutions.

Collaborations

Zheng has had the opportunity to collaborate with esteemed colleagues, including Feng Li and King Chuen Li. These collaborations have likely enhanced his research endeavors, facilitating the development of groundbreaking technologies and compounds that could change the landscape of medical treatments and diagnostics.

Conclusion

In summary, Zheng Li's contributions to the field of biotechnology and medical innovation through his patents on VEGFR-targeting compounds and integrin antagonists highlight his role as a leading inventor in Houston, TX. His innovative work continues to have a significant impact on therapeutic and diagnostic applications, pushing the boundaries of what is possible in medical science.